Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Sanofi-Aventis in Cancer Drug Deal with Exelixis

By Pharmaceutical Processing | May 28, 2009

SOUTH SAN FRANCISCO, Calif. (AP) — Biotechnology company Exelixis Inc. said Thursday it will collaborate with Sanofi-Aventis to develop cancer treatments in a deal that could be worth more than $1 billion. The companies will work together on drugs that block a type of enzyme called phosphoinositide-3 kinase, which is often found in tumors and leads to cell spreading, survival, and resistance to chemotherapy and radiation treatment. Exelixis will receive an upfront payment of $140 million, plus $21 million in guaranteed research funding over three years. Exelixis could get more than $1 billion if the drug candidates advance through testing and regulatory processes, and reach sales milestones. It could also receive royalties on sales. As part of the agreement, Sanofi-Aventis gains the worldwide license rights to XL147 and XL765, a pair of Exelixis drug candidates. Exelixis is running early human trials on the two drugs, and Sanofi-Aventis will be responsible for all future testing, regulatory submissions, sales and manufacturing. Exelixis is responsible for the ongoing trials, and it may conduct some of the future trials of drug candidates developed under the collaboration. South San Francisco, Calif.-based Exelixis in March predicted between $140 million and $170 million in revenue for all of 2009. It reported $29.6 million in revenue last year from collaborations with Bristol-Myers Squibb Co., Wyeth, and Genentech Inc. Shares of Exelixis spiked $1.33, or 29.5 percent, to $5.84 in premarket activity. Its shares have ranged from $2.11 to $7.35 over the past year.

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE